Agile Therapeutics Inc. (NASDAQ:AGRX)‘s stock had its “buy” rating restated by stock analysts at FBR & Co in a research report issued on Tuesday. They currently have a $16.00 price objective on the specialty pharmaceutical company’s stock. FBR & Co’s price objective suggests a potential upside of 125.04% from the company’s current price.

The analysts wrote, “Agile Therapeutics Receives a Buy from FBR Capital | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=79dde734e8&wpp_id=459256’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Agile Therapeutics Receives a Buy from FBR Capital”

Separately, Noble Financial reaffirmed a “buy” rating and issued a $15.00 target price on shares of Agile Therapeutics in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $14.83.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Shares of Agile Therapeutics (NASDAQ:AGRX) opened at 7.11 on Tuesday. Agile Therapeutics has a 12-month low of $5.32 and a 12-month high of $10.41. The firm’s market cap is $204.43 million. The stock’s 50 day moving average is $7.31 and its 200-day moving average is $7.13.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, November 7th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.08. On average, analysts anticipate that Agile Therapeutics will post ($1.24) EPS for the current fiscal year.

A number of large investors have recently modified their holdings of AGRX. Teachers Advisors Inc. raised its stake in shares of Agile Therapeutics by 30.2% in the second quarter. Teachers Advisors Inc. now owns 19,401 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 4,497 shares in the last quarter. TFS Capital LLC bought a new stake in shares of Agile Therapeutics during the second quarter worth approximately $164,000. Rice Hall James & Associates LLC raised its stake in shares of Agile Therapeutics by 1.2% in the third quarter. Rice Hall James & Associates LLC now owns 25,631 shares of the specialty pharmaceutical company’s stock worth $179,000 after buying an additional 314 shares in the last quarter. AlpInvest Partners B.V. bought a new stake in shares of Agile Therapeutics during the second quarter worth approximately $211,000. Finally, BlackRock Investment Management LLC raised its stake in shares of Agile Therapeutics by 9.3% in the second quarter. BlackRock Investment Management LLC now owns 45,455 shares of the specialty pharmaceutical company’s stock worth $346,000 after buying an additional 3,855 shares in the last quarter. 84.33% of the stock is currently owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

5 Day Chart for NASDAQ:AGRX

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.